Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.

Barth RJ Jr, Fisher DA, Wallace PK, Channon JY, Noelle RJ, Gui J, Ernstoff MS.

Clin Cancer Res. 2010 Nov 15;16(22):5548-56. doi: 10.1158/1078-0432.CCR-10-2138. Epub 2010 Sep 30.

2.

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.

Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, Scharenborg NM, Van De Rakt M, Hesselink EJ, Figdor CG, Adema GJ, Punt CJ.

Anticancer Res. 2010 Dec;30(12):5091-7.

PMID:
21187495
3.

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.

Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.

Blood. 1999 Apr 1;93(7):2411-9.

4.

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.

Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, Kim H, Lee H.

J Transl Med. 2011 Oct 20;9:178. doi: 10.1186/1479-5876-9-178.

5.

A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.

Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ.

Ann Surg Oncol. 2007 Feb;14(2):869-84. Epub 2006 Nov 14.

PMID:
17103257
6.

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG.

Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19.

7.

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.

Blood. 2002 Mar 1;99(5):1517-26.

8.

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.

Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ.

J Immunother. 2008 Jul-Aug;31(6):591-8. doi: 10.1097/CJI.0b013e31817fd90b.

9.

Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.

Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, Szczepiorkowski ZM, Tosteson TD, Rhodes CH, Wishart HA, Lewis LD, Ernstoff MS.

J Immunother. 2011 May;34(4):382-9. doi: 10.1097/CJI.0b013e318215e300.

10.

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF.

J Immunother. 2002 Nov-Dec;25(6):500-8.

PMID:
12439347
11.

Dendritic cell gene therapy.

Onaitis M, Kalady MF, Pruitt S, Tyler DS.

Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. Review.

PMID:
12487060
12.

Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.

Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F.

Br J Haematol. 2010 Sep;150(5):554-64. doi: 10.1111/j.1365-2141.2010.08286.x. Epub 2010 Jul 7.

13.

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ.

J Virol. 2008 Feb;82(4):1968-79. Epub 2007 Dec 5.

14.

Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.

Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L.

J Immunother. 2007 Oct;30(7):762-72.

PMID:
17893568
15.

Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment.

Chen HW, Huang HI, Lee YP, Chen LL, Liu HK, Cheng ML, Tsai JP, Tao MH, Ting CC.

Cancer Immunol Immunother. 2002 Aug;51(6):341-8. Epub 2002 Jun 14.

PMID:
12111122
16.

Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.

Lesterhuis WJ, de Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, Ruers TJ, Adema GJ, Punt CJ.

Ann Oncol. 2006 Jun;17(6):974-80. Epub 2006 Apr 6.

17.

A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.

Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ.

Clin Cancer Res. 2002 Apr;8(4):1021-32.

18.

Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.

Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M.

Cancer Immunol Immunother. 2006 Mar;55(3):268-76. Epub 2005 Jul 21.

PMID:
16034561
19.

Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.

Gatza E, Okada CY.

J Immunol. 2002 Nov 1;169(9):5227-35. Erratum in: J Immunol. 2003 May 15;170(10):following 5332.

20.

Dendritic cell vaccination of patients with metastatic colorectal cancer.

Burgdorf SK.

Dan Med Bull. 2010 Sep;57(9):B4171.

PMID:
20816019
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk